Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study: Shares Rose Over 5%

March 14, 2019 12:33 AM EDT | By Team Kalkine Media
 Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study: Shares Rose Over 5%

Imugene Limited (ASX:IMU) is into the operations of immuno-oncology. It is in its clinical stage and is into the development of a range of new and novel immunotherapies which helps to activate the immune system of cancer patients to treat and eradicate tumours. The company has a unique platform technology that tries to harness the immune system of the body to generate antibodies against tumours, in order to get a similar or greater response than synthetically manufactured monoclonal antibody therapies.

The company today on 14 March 2019 announced that it had given a dose of its HER-Vaxx (IMU-131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients to the first patient in an open-label, randomised multi-centre Phase 2 study. The patient in the study was dosed at the Oncological Institute in Chisinau, the capital of Moldova, in Eastern Europe.

HER-Vaxx is a potentially pioneering vaccine for cancer treatments. The vaccine produces antibody which is a response against a cancer growth signal receptor protein (HER-2). This is found on the cell surface of multiple cancers including breast and gastric cancers.

The MD and CEO of the company Leslie Chong said, that after the good results seen in the recently completed Phase 1b trial there is a strong medical investigator interest. In the trial, 11 out of 14 evaluable patients showed clinically meaningful responses. The company will provide regular recruitment updates as the Phase 2 study moves toward completion in 2020. It is an important achievement for the company to have commenced the Phase 2 study, and important for several medical professionals as well, who are looking out for treatments for patients who does not have many medical options after being diagnosed with advanced HER-2 positive gastric cancer.

As per the report of the Phase 1b HER-Vaxx study, there are no safety or toxicity issues. All patients evaluated responded with an increased antibody. One patient saw a complete response, five had a partial response, and four recorded a stabilisation of their disease.

The Phase 2 HER-Vaxx study has been an indicator of success, safety and the immune response in sixty-eight patients who are diagnosed with metastatic gastric cancer. Across multiple sites in Asia, Eastern Europe and India this Phase 2 trial is being conducted, where it is difficult for patients to access approved antibody treatments such as Herceptinâ and Perjetaâ, which is marketed by Swiss multinational Roche Holding AG.

On the price-performance front, the stock of Imugene Limited is currently trading at $0.020 with an increase of ~5.26 per cent during the day’s trade, with a market capitalisation of $68.59 million (AEST 01:29 PM). The stock has generated a YTD return of 5.56% and a negative return of 17.39% over the past six months. It had a 52-week high price of $0.040 and a 52-week low price of $0.015, with an average trading volume of ~4.28 million.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.